Form 4: Apogee Therapeutics CEO Michael Henderson Sells Shares
SEC Form 4 Filing
Apogee Therapeutics CEO Michael Henderson sold shares of the company's common stock on January 8, 2025, according to a Form 4 filing with the SEC.
Summary
- Michael Henderson, CEO of Apogee Therapeutics, sold shares of the company's common stock on January 8, 2025.
- The sales were executed in two transactions at weighted average prices of $48.72 and $49.38.
- A total of 12,132 shares were sold in the first transaction and 2,868 shares in the second.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 25, 2023.
- Following the reported transactions, Henderson beneficially owns 1,309,487 shares of Apogee Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock sales by an insider. It doesn't inherently convey positive or negative sentiment, but the market's reaction to insider selling can vary.
Industry Context
Insider selling can be interpreted in various ways by the market. It could be due to personal financial planning or diversification, but it can sometimes raise concerns if the selling is substantial or occurs without a clear pre-arranged plan.
Key Dates
| Date | Description |
|---|---|
| 09/25/2023 | Date of adoption of Rule 10b5-1 trading plan |
| 01/08/2025 | Date of stock sale transactions |
| 01/10/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.